ARMoR

top of page

Our Mission

Develop and implement evidence-based policy to support innovation and access to life-saving antimicrobials

Over 1.27 million deaths can be attributed to antimicrobial resistance every year
Without serious intervention, studies estimate antimicrobial resistance could reach 10+ million fatalities each year by 2050.
90% of the direct death toll and over 99.5% of AMR–related deaths among children under five occur in LMICs

A 3 Part Solution

INNOVATION

We haven't discovered, developed, and commercialised any novel antimicrobials in the past 40 years
In order to keep up with the rate of resistance, we need at least 4 novel antimicrobials every decade
Market-shaping mechanisms can be used to incentivise this much needed innovation

ACCESS

Of the last 18 antimicrobials to come to market, only the US, UK, Sweden and France have access to more than seven of them. Japan has access to five and Canada just two.
New life-saving antibiotics are rarely available in LMICs, which have the highest AMR burden
We need policies and mechanisms in place to ensure that novel antimicrobials are accessible where they are needed most

STEWARDSHIP

In order to ensure that antibiotics have a long lifespan, we need to ensure that they are being used appropriately
To do this, we need surveillance programs, better diagnostic tests, agricultural use guidelines, etc.

French Politicians

What We Do

01

Conduct research to support national governments and multilateral stakeholders in efforts to implement pull incentives

02

Design effective policies that incentivise the development of novel antimicrobials and ensure global access where it is needed most.

03

Mobilise stakeholders to support and advocate for these policies.

04

Support implementation of these policies to ensure they are carried out in the most effective way to support the public good

bottom of page